No Data
No Data
Piper Sandler Reaffirms Their Hold Rating on Supernus Pharmaceuticals (SUPN)
Supernus Pharmaceuticals CEO Jack Khattar to Speak at Upcoming Investor Conferences in March 2025
Does The Market Have A Low Tolerance For Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Fundamentals?
Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Small Cap Pharma Stocks to Buy Now?
Supernus Pharmaceuticals' Earnings Call Highlights Growth and Challenges
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference
Unlock the Full List